Daily low-dose aspirin halves diabetes incidence
-
The commercials on TV are filled with all kinds of drugs targeting (pre)diabetes, obesity and insulin resistance. All such drugs invariably come with a long list of very serious, even deadly, side effects and mainstream medicine is not a step closer to preventing or curing diabetes than it was 50 years ago. Sugar continues to be demonized, while low-carb diets and fasting are all the rage now and have been for the last 10-15 years. None of the drugs on the market for preventing diabetes can boast more than single-digit risk reduction of diabetes, and pharma companies still consider such results a monumental “success”. Well, it looks like humble aspirin, even at the low-dose (100mg daily) commonly prescribed for cardiovascular issues, can reduce the incidence of diabetes by about 50%. It is a shame the study did not examine the effects of higher aspirin doses, as aspirin’s pro-metabolic effects are known to be dose-dependent. We can thank Big Pharma and the public health authorities for that study handicap given their relentless fearmongering about aspirin “risks” and how it should be used only if a doctor prescribes it and only if other options are not available. Now, the study did find a small increase in bleeding risk with aspirin, but paradoxically this rusk is actually more pronounced at lower aspirin doses than at higher ones. Thus, a higher dose in the range of, say, 300mg-500mg would probably have an even stronger anti-diabetic effect while reducing bleeding risks.
https://cardiab.biomedcentral.com/articles/10.1186/s12933-025-02802-9
“…The primary outcome was the onset of T2DM, defined as a new diagnosis accompanied by antidiabetic prescriptions lasting more than 30 days. Gastrointestinal bleeding was assessed as the safety endpoint. Over the follow-up period, 488 new cases of T2DM were documented (15.6% of the total population), with 174 cases occurring in the aspirin group (22.3 per 1000 person-years) and 314 in the non-aspirin group (40.2 per 1000 person-years), indicating a significantly lower incidence of diabetes among aspirin-treated individuals. Given the difference in comorbidity rates between groups, a Cox regression analysis was conducted across the entire follow-up period, showing that aspirin use was associated with a 47% reduction in the risk of developing T2DM (HR 0.53, 95% CI 0.44–0.64, p < 0.001). However, aspirin use was also linked to an increased risk of gastrointestinal bleeding (4.9% vs 3.1%, p < 0.05). Kaplan–Meier survival curves confirmed a significantly lower cumulative incidence of T2DM in the aspirin-treated group (log-rank test p < 0.0001)….Daily treatment with 100 mg aspirin was associated with approximately a 50% reduction in the incidence of new-onset T2DM, but also with an increased risk of gastrointestinal bleeding, in elderly individuals with prediabetes.”
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Register Login